Drug Combination Details
| General Information of the Combination (ID: C04358) | |||||
|---|---|---|---|---|---|
| Name | Glucocorticoids NP Info | + | Selumetinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Cells derived from acute lymphoblastic leukemia patients | Acute lymphoblastic leukemia | Homo sapiens | |||
| In-vivo Model | For a xenograft model, primagraft cells were injected intrafemorally into NOD SCID Gamma null (NSG) mice. | |||||
| Experimental
Result(s) |
A selumetinib-dexamethasone combination may be highly effective in RAS pathway-mutated acute lymphoblastic leukemia. | |||||
